Hester Biosciences Limited (IN:HESTERBIO)
:HESTERBIO
Want to see IN:HESTERBIO full AI Analyst Report?
Top Page
Hester Biosciences Limited
(HESTERBIO)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹2,160.00
▲(34.52% Upside)
Action:Reiterated
Date:05/28/26
The score is primarily supported by improving financial performance (profitability rebound, better leverage, and positive recent free cash flow). Technicals are bullish but look overheated (very high RSI), and valuation is fair rather than compelling with a low dividend yield.
Positive Factors
Stable multi-year revenue growth
Consistent multi-year revenue expansion, including a 2026 re-acceleration, indicates durable demand for veterinary vaccines and products. This supports scale advantages, more predictable production planning, and strengthens competitive position in poultry and livestock health markets over the medium term.
Negative Factors
Margin and cash-flow volatility
Large year-to-year swings in gross margins and net income have been persistent, creating unpredictability in earnings quality. Such volatility complicates budgeting, weakens stakeholder confidence, and raises execution risk for sustaining margins through input cost or demand shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable multi-year revenue growth
Consistent multi-year revenue expansion, including a 2026 re-acceleration, indicates durable demand for veterinary vaccines and products. This supports scale advantages, more predictable production planning, and strengthens competitive position in poultry and livestock health markets over the medium term.
Read all positive factors
Hester Biosciences Limited (HESTERBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹17.47B
Dividend Yield0.44%
Average Volume (3M)308.00
Price to Earnings (P/E)30.4
Beta (1Y)0.54
Revenue Growth6.91%
EPS Growth102.41%
CountryIN
Employees642
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)52.41
Shares Outstanding8,506,865
10 Day Avg. Volume428
30 Day Avg. Volume308
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.88
Price to Sales (P/S)3.12
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hester Biosciences Limited Business Overview & Revenue Model
Company Description
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both ...
How the Company Makes Money
Hester Biosciences makes money primarily by selling animal healthcare products, with a strong emphasis on veterinary vaccines (veterinary biologicals). Revenue is generated from (1) domestic sales in India to poultry and livestock industry custome...
Hester Biosciences Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
66
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.00B | 3.33B | 3.11B | 3.05B | 2.66B | 2.35B |
| Gross Profit | 2.00B | 1.69B | 2.08B | 972.64M | 1.89B | 1.66B |
| EBITDA | 670.92M | 866.58M | 649.76M | 582.46M | 619.20M | 731.93M |
| Net Income | 438.44M | 556.39M | 274.88M | 188.89M | 266.27M | 393.20M |
Balance Sheet | ||||||
| Total Assets | 6.75B | 6.78B | 6.53B | 6.62B | 6.70B | 5.62B |
| Cash, Cash Equivalents and Short-Term Investments | 281.58M | 274.90M | 72.19M | 153.04M | 148.17M | 252.20M |
| Total Debt | 2.14B | 1.95B | 2.13B | 2.44B | 2.74B | 2.28B |
| Total Liabilities | 3.24B | 3.10B | 3.27B | 3.59B | 3.81B | 2.95B |
| Stockholders Equity | 3.38B | 3.60B | 3.14B | 2.92B | 2.80B | 2.60B |
Cash Flow | ||||||
| Free Cash Flow | 91.06M | 417.03M | 439.20M | 237.37M | -541.66M | -869.02M |
| Operating Cash Flow | 174.78M | 595.31M | 645.11M | 481.34M | 235.96M | 88.08M |
| Investing Cash Flow | -22.74M | -49.00M | -190.03M | -226.54M | -769.99M | -1.17B |
| Financing Cash Flow | -155.89M | -421.53M | -517.17M | -260.45M | 417.58M | 1.12B |
Hester Biosciences Limited Technical Analysis
Positive
1605.75
Price Trends
1740.21
Positive
1605.54
Positive
1677.07
Positive
Market Momentum
78.16
Positive
64.71
Neutral
84.31
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HESTERBIO, the sentiment is Positive. The current price of 1605.75 is below the 20-day moving average (MA) of 1971.58, below the 50-day MA of 1740.21, and below the 200-day MA of 1677.07, indicating a bullish trend. The MACD of 78.16 indicates Positive momentum. The RSI at 64.71 is Neutral, neither overbought nor oversold. The STOCH value of 84.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HESTERBIO.
Hester Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹17.47B | 30.40 | ― | 0.44% | 6.91% | 102.41% | |
60 Neutral | ₹27.96B | 30.24 | ― | 0.49% | -0.32% | -22.18% | |
59 Neutral | ₹31.59B | 12.48 | ― | ― | 8.53% | 67.93% | |
57 Neutral | ₹35.81B | 55.94 | ― | 0.03% | 15.15% | -7.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ₹21.41B | -20.11 | ― | 0.08% | 10.73% | -31.79% |
* Healthcare Sector Average
IN:HESTERBIO
Hester Biosciences Limited
2,053.65
312.49
17.95%
IN:GUFICBIO
Gufic Biosciences Limited
357.05
1.20
0.34%
IN:INDOCO
Indoco Remedies Limited
231.90
-52.40
-18.43%
IN:MOREPENLAB
Morepen Laboratories Limited
51.02
-10.22
-16.69%
IN:UNICHEMLAB
Unichem Laboratories Limited
448.70
-137.90
-23.51%
Hester Biosciences Limited Corporate Events
Hester Biosciences Discloses Resignation of Non-Executive Director Ravin Gandhi
May 12, 2026
Hester Biosciences Limited announced that non-executive director Ravin Gandhi has resigned from the board with effect from 12 May 2026, citing professional and personal commitments that prevent him from devoting sufficient time to company affairs....
Hester Biosciences Non-Executive Director Ravin Gandhi Resigns, Alternate Director Role Ends
May 12, 2026
Hester Biosciences has announced the resignation of non-executive director Ravin Gandhi, effective 12 May 2026, after he cited ongoing professional and personal commitments that prevent him from devoting sufficient time to board duties and company...
Hester Biosciences to Shut Trading Window Ahead of FY26 Results
Mar 26, 2026
Hester Biosciences Limited has announced that its trading window for dealing in the company’s equity shares will be closed from 1 April 2026. The window will reopen 48 hours after the financial results for the quarter and year ended 31 March...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.